Headquartered in Washington, DC Fiscal year ends December NASDAQ: VNDA vandapharma.com
Vanda Pharmaceuticals is a global biopharmaceutical company focused on the development and commercialization of innovative therapies for high unmet medical needs. The company markets Fanapt (iloperidone) for schizophrenia, HETLIOZ (tasimelteon) for Non-24-Hour Sleep-Wake Disorder, and PONVORY (ponesimod) for relapsing forms of multiple sclerosis. In 2026, Vanda received FDA approval for BYSANTI (milsaperidone) for bipolar I disorder and schizophrenia, and launched NEREUS (tradipitant) for prevention of motion-induced vomiting via a direct-to-consumer platform. The company's pipeline includes late-stage programs for BYSANTI in major depressive disorder, NEREUS for GLP-1 receptor agonist-induced vomiting, VQW-765 for social anxiety disorder, and imsidolimab (a biologic) for generalized pustular psoriasis. Vanda trades on Nasdaq under the ticker VNDA. Updated
Friday afternoon's top analyst upgrades and downgrades included BP, Carvana, Iron Mountain, Latch and LivePerson.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Wednesday, including Amazon, Caterpillar, Disney, EA, Target and more.
Vanda Pharma shares jumped on Wednesday after the company announced an update from the FDA regarding its treatment for nighttime sleep disturbances associated with Smith-Magenis syndrome.
Chris Lange Vanda Pharmaceuticals took another big step forward in the fight against COVID-19 on Tuesday morning.
Chris Lange Tuesday's top analyst upgrades and downgrades included Avaya, Biogen, Broadcom, Chevron, Domino's Pizza, eBay, MGIC Investment, RealReal, Sprout Social, T-Mobile, Zoom Video Communications and Zynga.
Vanda Pharma shares dropped early to start out the week after the frim announced that it received a Complete Response Letter from the FDA.
Chris Lange The top analyst upgrades, downgrades and initiations seen on Thursday included Allstate, Corning, DexCom, Lam Research, On Deck, Qualcomm, Spotify, Western Digital and Whiting Petroleum.
The top analyst upgrades, downgrades and initiations seen on Thursday included AT&T, Caterpillar, Dollar General, Electronic Arts, Etsy, Facebook, Spirit Airlines, Tesla and Xilinx.
The top analyst upgrades, downgrades and initiations seen on Wednesday included DowDuPont, Electronic Arts, Estee Lauder, Exxon, Generac, Match, Nasdaq, Novartis, PayPal, Snap and Vishay.
The top analyst upgrades, downgrades and initiations seen on Tuesday included Abbott Laboratories, Apple, Apptio, Cheniere Energy, First Solar, Kratos Defense & Security Solutions, Smartsheet, UPS and Waste Management.
Vanda Pharmaceuticals shares made a solid gain on Monday after the firm announced results from a midstage trial of patients with idiopathic and diabetic gastroparesis.
Chris Lange The top analyst upgrades, downgrades and other research calls from Monday include AMD, Chevron, GM, Intel, Merck, Nokia and Under Armour.
The top analyst upgrades, downgrades and other research calls from Tuesday include Alibaba, BHP Billiton, Cintas, Monsanto, Schlumberger, Shopify, Hess and Western Digital.
Needless to say, the past two years have been rough on biotech. The question for investors is which of the stocks hold the best potential in 2017.
Jefferies highlights top growth stocks to buy each week, and this week is no exception. These four all make good sense now and have outstanding upside potential.
Vanda Pharmaceuticals is a global biopharmaceutical company focused on the development and commercialization of innovative therapies for high unmet medical needs.
The Wall Street consensus 12-month price target for VNDA is $11.75.
